784. A Retrospective Report of Efficacy and Tolerability of Low Daily Dose Ketamine for Depression and Anxiety in a Large Population Sample
The International Journal of Neuropsychopharmacology September 1, 2026 A Nunes, J E Cunningham, B Leden et al.
Abstract Background Use of intravenous ketamine or intranasal esketamine for depression is frequently limited due to resource requirements and cost. Alternative treatment models have used oral, sublingual or intranasal racemic ketamine, but optimal doses and frequency of administration remain unclear. Dosing modelled from the standard 0.5-1.0mg/kg twice weekly IV ketamine result in transient...